Plus Therapeutics (NASDAQ:PSTV) Issues Earnings Results

Plus Therapeutics (NASDAQ:PSTV) posted its quarterly earnings data on Thursday. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.16), Zacks reports. The business had revenue of $1.80 million during the quarter, compared to analysts’ expectations of $1.19 million.

Plus Therapeutics Stock Performance

Shares of Plus Therapeutics stock traded down $0.35 on Friday, reaching $1.17. 2,457,898 shares of the stock were exchanged, compared to its average volume of 3,921,736. The firm’s 50 day moving average is $1.11 and its 200-day moving average is $1.24. The firm has a market cap of $6.90 million, a PE ratio of -0.46 and a beta of 0.73. Plus Therapeutics has a one year low of $0.24 and a one year high of $2.67.

Analyst Ratings Changes

Several brokerages have weighed in on PSTV. HC Wainwright dropped their price objective on shares of Plus Therapeutics from $8.00 to $5.50 and set a “buy” rating for the company in a research note on Friday. Ascendiant Capital Markets dropped their price target on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research report on Monday, December 9th. Finally, D. Boral Capital reissued a “buy” rating and set a $9.00 price target on shares of Plus Therapeutics in a research report on Friday.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.